ZYME News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

ZY

Mkt Cap

$1.80B

Volume

478.45K

Next Earnings

November 5th

Loading chart

ZY

ZYMEZymeworks Inc.

ZYME

Pay with—

Available Balance0.00

ZY

Mkt Cap

$1.85B

Volume

478.45K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial ResultsZymeworks Inc. announced it will report Q3 2026 financial results on November 9, 2026, without a conference call. The company will participate in multiple investor conferences in November, including events hosted by Wolfe Research, Stifel, Truist Securities, and Jefferies in New York and London. The biotech company continues executing its strategy of building a diversified portfolio of healthcare assets including commercial products like YUPELRI® and pipeline candidates.GlobeNewswire Inc. · Oct 15, 2026

Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma AcquisitionZymeworks completed its acquisition of Theravance Biopharma, adding YUPELRI to its portfolio and providing durable cash flows. The company updated 2026 guidance to $278-292 million in total revenue and $114-128 million in Adjusted EBITDA. The acquisition is expected to deliver mid-teens IRR with immediate accretive revenue and cash flow, financed through a $350 million non-recourse note from OMERS and $217.5 million in existing cash.GlobeNewswire Inc. · Sep 28, 2026

JAZZ Rises on Updated OS Results From Gastric Cancer StudyJazz Pharmaceuticals announced second interim results from the HERIZON-GEA-01 study showing statistically significant overall survival improvements for Ziihera plus chemotherapy versus standard of care trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The three-drug regimen of Ziihera plus Tevimbra and chemotherapy also demonstrated improved OS hazard ratios with longer follow-up. These results support the recent FDA label expansion of Ziihera for first-line treatment in this indication, significantly expanding its commercial opportunity.Zacks Investment Research · Sep 1, 2026

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026Zymeworks Inc. announced it will report second quarter 2026 financial results on August 6, 2026, but will not host an earnings conference call due to its pending acquisition of Theravance Biopharma. The company plans to provide updates on the combined business following the expected closing of the acquisition.GlobeNewswire Inc. · Jul 16, 2026

Zymeworks to Acquire Theravance Biopharma, Inc.Zymeworks announced a definitive agreement to acquire Theravance Biopharma for $17 per share ($929 million) to gain YUPELRI®, a nebulized LAMA for COPD treatment. The acquisition is financed through a $350 million non-recourse note from OMERS Life Sciences and Zymeworks' cash, with the deal expected to be accretive to earnings and cash flow. YUPELRI® generated $266.6 million in U.S. net sales in 2025 with 12% growth, positioning Zymeworks to diversify its revenue streams and fund R&D initiatives.GlobeNewswire Inc. · Jun 29, 2026

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026Zymeworks presented Phase 1 data for ZW191, a folate receptor alpha-targeting antibody-drug conjugate, showing a confirmed objective response rate of 78.6% in FRα-positive platinum-resistant ovarian cancer patients and 47.4% in FRα-negative patients. The drug demonstrated a favorable tolerability profile with median progression-free survival of 7.6 months across ovarian and endometrial cancer cohorts. Patient recruitment in dose optimization cohorts has been completed, supporting continued clinical development.GlobeNewswire Inc. · Jun 14, 2026

Zymeworks Announces Participation in Upcoming Investor ConferencesZymeworks Inc. announced its participation in three upcoming investor conferences: the 2026 Stifel Virtual Targeted Oncology Forum (May 20), TD Cowen 7th Annual Oncology Innovation Summit (May 27), and 2026 Jefferies Global Healthcare Conference (June 3). The company will engage in fireside chats and one-on-one meetings to discuss its portfolio of licensed healthcare assets and pipeline of novel biotherapeutics.GlobeNewswire Inc. · May 13, 2026

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting PlatformZymeworks announced six poster presentations at AACR 2026 showcasing preclinical data from its antibody-drug conjugate (ADC) pipeline, including novel RAS-targeting platforms and multiple first-in-class programs. The company highlighted efficacy and favorable tolerability across solid tumor models, with clinical data from the Phase 1 ZW191 trial to be presented in an oral presentation on April 21.GlobeNewswire Inc. · Apr 17, 2026

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of GrowthZymeworks Inc. announced the full-time appointments of Dr. Adam Schayowitz as Executive Vice President and Head of R&D, and Scott Platshon as Executive Vice President and Chief Business Officer, effective April 9, 2026. Both executives, previously in interim roles, will report to CEO Kenneth Galbraith. The appointments come as Zymeworks focuses on executing its pipeline strategy, managing licensed assets including Ziihera® (zanidatamab-hrii) and pasritamig, and advancing its asset aggregation strategy to drive long-term shareholder value.GlobeNewswire Inc. · Apr 9, 2026

Zymeworks Appoints Kristin Stafford as Chief Financial OfficerZymeworks Inc. announced the appointment of Kristin Stafford as Chief Financial Officer effective April 1, 2026. Stafford brings extensive experience from Royalty Pharma in strategic planning, capital allocation, and executing complex transactions. The appointment comes as Zymeworks continues advancing its pipeline of biotherapeutics and executing strategic priorities.GlobeNewswire Inc. · Apr 1, 2026

to start trading

ZY

ZYMEZymeworks Inc.

ZYME

Pay with—

Available Balance0.00

Your PositionYou don't own any ZYME yet.

Related Tickers

Earnings